



**This sample document shows how the ONWARD RYSTIGGO Start Form (US-P-OT--2200050) could be completed. For illustrative purposes only. Not an actual patient.**

## **Start Form for RYSTIGGO® (rozanolixizumab-noli) Injection for Subcutaneous Use**

### **Instructions for Prescribers or Rendering Providers**

To get a patient who has been prescribed RYSTIGGO started in ONWARD™, please follow these steps:

- 1.** Complete the RYSTIGGO Start Form, providing all required information.
- 2.** Have your patient read and sign the Patient Authorization sections of the Start Form.
- 3.** Fax the completed Start Form to 1-833-FAX-UCB1 (**1-833-329-8221**).

### **Instructions for Patients**

- 1.** Read and sign the Patient Authorization sections of the Start Form to enroll in ONWARD.
- 2.** If you would like us to communicate with you via email and/or text, make sure to check the appropriate consent boxes and provide your email address and/or mobile phone number.
- 3.** You will receive a call from an ONWARD Care Coordinator to discuss the support services being requested by you and/or your physician. Please note that when you receive this call, you may see "ONWARD" on your caller ID.

If you have any questions, please call us at 1-844-ONWARD1 (**1-844-669-2731**). A program associate is available to help you **Monday through Friday, 8 AM to 8 PM, Eastern Time**.

ONWARD is provided as a service of UCB and is intended to support the appropriate use of UCB medicines. ONWARD may be amended or canceled at any time without notice. Some program and eligibility restrictions may apply.

RYSTIGGO® is a registered trademark, and ONWARD™ is a trademark, of the UCB Group of Companies.  
©2023 UCB, Inc. Smyrna, GA 30080. All rights reserved. US-P-RZ-MG-2300123

# RYSTIGGO® (rozanolizumab-noli) Injection for Subcutaneous Use Start Form

FAX:  
1-833-FAX-UCB1 (1-833-329-8221)

ENROLL ONLINE:  
ONWARDhcp-enroll-RYSTIGGO.com

QUESTIONS? CALL:  
1-844-ONWARD1 (1-844-669-2731)

Services Requested:  Benefit Investigation  Financial Assistance  PA Appeal Support  Care Coordinator Support  
 Claim Denial Support  Patient Assistance Program (PAP) - Consent Required: see page 4

\* indicates required field

## Step 1: Patient Information

New to Therapy  On Therapy

First Name\* **Jane** Middle Initial **M** Last Name\* **Smith**  
 Date of Birth\* (MM/DD/YYYY) **08-13-1981** Phone Number\* **913-338-2234**  Home  Cell Gender: M  F  Other   
 Street Address\* **1234 Carter Street** Apt# \_\_\_\_\_  
 City **Kansas City** State **KS** ZIP\* **66101** Preferred Language:  English  Spanish  Other  
 Communication Preference:  Email  Phone  Text Email **janemarysf81@aol.com**

## Caregiver Information

By providing this information, you authorize ONWARD™ to communicate with this person regarding your health condition and services provided by the program.

First Name \_\_\_\_\_ Last Name \_\_\_\_\_ Relationship to Patient \_\_\_\_\_  
 Phone \_\_\_\_\_  Home  Cell Primary Point of Contact:  Patient  Caregiver  
 Email \_\_\_\_\_  Caregiver is authorized legal representative of the patient

## STEP 2: Insurance Information\*

**NOTE:** You may attach copies of the front and back of the patient's insurance card(s) in lieu of completing this section.

<input type="checkbox"/> Check here if patient does not have insurance	PRIMARY INSURANCE	SECONDARY INSURANCE	OTHER
INSURANCE PROVIDER	<b>BCBS</b>		
INSURANCE PHONE#	<b>913-550-1234</b>		
CARDHOLDER NAME	<b>Jane M Smith</b>		
RELATIONSHIP TO PATIENT	<b>Self</b>		
MEMBER ID	<b>123567-8904</b>		
GROUP#	<b>3456</b>		
BIN#	<b>1234</b>		
PCN#	<b>7891</b>		

## STEP 3: Prescriber/Rendering Provider Information

Prescriber First Name\* **Jessica** Prescriber Last Name\* **Barry**  
 Specialty **Neurology** NPI#\* **5678912345** Tax ID# **1234567893**  
 Rendering Provider **Cathy Mackey** Rendering Provider NPI **3456789123**  
 Practice/Clinic Name **Barry Medical**  
 Address\* **9087 Field Street**  
 City **Kansas City** State **KS** ZIP **66401**  
 Office Phone#\* **913-902-2038** Office Fax# **913-902-2037**  
 Office Contact Name **John Doe** Office Contact Email \_\_\_\_\_  
 Office Contact Phone# \_\_\_\_\_ Office Contact Communication Preference:  Phone  Email

## STEP 4: Product Acquisition and Preferred Site of Care

### Method of Acquisition

Buy & Bill  Specialty Pharmacy

Provide benefit coverage for the following site(s) of care (check all that apply):

In Office  Home Infusion  Ambulatory Infusion Center  Hospital Outpatient

Preferred Site of Care:  Check here if patient has already been referred.

Site of Care Name \_\_\_\_\_ NPI# \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

Please provide assistance locating in-network infusion site options

## STEP 5: Clinical Information

ICD-10 Diagnosis\*  G70.00  G70.01  Other \_\_\_\_\_ MGFA Classification (I, II, III, IV, V): **III**

MG-ADL Score **19** Date of Assessment **06/11/23**

AChR Antibody Test:  Positive  Negative  Not Known MuSK Antibody Test:  Positive  Negative  Not Known

### Current Therapies:

Eculizumab  Rituximab  
 Efgartigimod  IVIG  
 Ravulizumab  SCIG  
 Oral Corticosteroids  PLEX  
 Acetylcholinesterase Inhibitors  
 Other \_\_\_\_\_

### Non-steroidal ISTs

Azathioprine  
 Cyclophosphamide  
 Cyclosporine  
 Methotrexate  
 Tacrolimus  
 Mycophenolate

### Previous Therapies:

Eculizumab  Rituximab  
 Efgartigimod  IVIG  
 Ravulizumab  SCIG  
 Oral Corticosteroids  PLEX  
 Acetylcholinesterase Inhibitors  
 Other \_\_\_\_\_

### Non-steroidal ISTs

Azathioprine  
 Cyclophosphamide  
 Cyclosporine  
 Methotrexate  
 Tacrolimus  
Mycophenolate

### Medical Allergies:

No allergies

## STEP 6: Prescription Information

Patient First & Last Name **Jane Smith** Date of Birth (MM/DD/YYYY) **08/13/1981**

Patient Weight (kg) **77** Date Weight Measured **06/27/2023**

Prescriber to indicate prescribed RYSTIGGO® dose:

MEDICATION	STRENGTH/FORM	DIRECTIONS FOR ADMINISTRATION	QTY	REFILLS
RYSTIGGO (rozanolixizumab-noli)	NDC 50474-980-79: 280 mg/2 mL (140 mg/mL) single-dose vial	<input type="checkbox"/> (Patient weight <50 kg) 420 mg (3mL) via subcutaneous infusion once weekly for 6 weeks	12 vials	3
		<input checked="" type="checkbox"/> (Patient weight ≥50 kg to <100 kg) 560 mg (4mL) via subcutaneous infusion once weekly for 6 weeks		
		<input type="checkbox"/> (Patient weight ≥100 kg) 840 mg (6mL) via subcutaneous infusion once weekly for 6 weeks	18 vials	

Administer subsequent treatment cycles based on clinical evaluation

Infusion Order:  Check box to initiate infusion order for RYSTIGGO.

### Attestation and Signature

By signing below, I certify: 1) This information is accurate to the best of my knowledge; 2) I am disclosing this information to UCB, their affiliates, agents, representatives, business partners, and service providers (together "UCB") to help enable treatment for this Patient; 3) The Patient is aware of, has consented to, and has directed my disclosure of their information to UCB so that UCB may contact the Patient to further enable services for those purposes and that such consent and direction applies to disclosures made through the duration of the Patient's therapy; 4) I will not seek reimbursement from any third party for the support UCB provides.

**Check For Prescribers Only:** In addition, I certify that the therapy is medically necessary, and I am licensed to prescribe the prescription medication identified in this form, the prescription complies with my state-specific prescribing requirements and I appoint UCB as my agent for the limited purposes of conveying this prescription by any means under applicable law only to the dispensing pharmacy. PRESCRIBER SIGNATURE: PRESCRIBER MUST MANUALLY SIGN AND DATE. RUBBER STAMPS AND SIGNATURE BY OTHER OFFICE PERSONNEL FOR THE PRESCRIBER WILL NOT BE ACCEPTED.

PRINT FIRST AND LAST NAME: **Jessica Barry**

Signature\* *Jessica Barry*

Dispense as Written (Date) **06/27/2023**

## Patient Authorization

### Please see next page for required HIPAA Authorization

#### **PAP Consent\* (Required for the Patient Assistance Program):**

By checking here, applicants authorize ONWARD™ PAP and its Administrators to obtain a consumer report. The consumer report, and the information derived from public and other sources, will be used to estimate income as part of the process to decide eligibility to receive free medication from the ONWARD PAP. Upon request, the ONWARD PAP will provide applicants with the name and address of the consumer reporting agency that provides the consumer report. For additional questions about eligibility, please call ONWARD at 1-844-669-2731 (1-844-ONWARD1).

---

#### **Text Message Consent Language:**

By checking here, you agree to receive text messages from UCB ONWARD for patient support. Message and data rates may apply. Message frequency will vary based on need. Text **"HELP"** to **844669** for help. Text **"STOP"** to **844669** to cancel. If you have questions, call 1-844-669-2731 (1-844-ONWARD-1). For more information on how UCB will use your information, please view our privacy policy at [www.ucb-usa.com/policy](http://www.ucb-usa.com/policy) and our text messaging terms and conditions at [www.ucbONWARD.com/Text-Terms-Conditions](http://www.ucbONWARD.com/Text-Terms-Conditions).

#### **Terms of Use**

##### **UCB ONWARD Patient Support Text Messaging Terms of Use:**

The UCB ONWARD Patient Support Text Messaging Program will send adherence and benefit information, as well as allow your Care Coordinator to check-in periodically. This text service is not medical information or medical advice and is not a replacement for seeking medical advice or care from your healthcare provider. Please consult your healthcare provider for any medical advice or information on your condition or treatments.

ONWARD text service is available on the following carriers: Participating carriers: AT&T, Sprint, Boost, Virgin, T-Mobile. T-Mobile is not liable for delayed or undelivered messages. Minor carriers: Aio Wireless, Alaska Communications Systems (ACS), Appalachian Wireless (EKN), Bluegrass Cellular, Boost Mobile, Carolina West Wireless, CellCom, Cellular One of East Central IL (ECIT), Cellular One of Northeast Arizona, Cellular One of Northeast Pennsylvania, Chariton Valley Cellular, Coral Wireless (Mobi PCS), Cricket, Cross, C-Spire (CellSouth), Duet IP (Maximum Communications New Core Wireless), Element Mobile (Flat Wireless), Epic Touch (Elkhart Telephone), GCI, Golden State, Google Voice, Hawkeye (Chat Mobility), Hawkeye (NW Missouri), Illinois Valley Cellular, Inland Cellular, iWireless (Iowa Wireless), Keystone Wireless (Immix Wireless/PC Man), Metro PCS, Mosaic (Consolidated or CTC Telecom), MTA Communications, MTPCS (Cellular One Nation), Nex-Tech Wireless, Panhandle Communications, Peoples Wireless, Pine Cellular, Pioneer, RINA, Sagebrush Cellular (Nemont), SI Wireless/Mobile Nation, Simmetry (TMP Corporation), SouthernLinc, SRT Wireless, Thumb Cellular, Union Wireless, United Wireless, U.S. Cellular, Viaero Wireless, Virgin Mobile, and West Central (WCC or 5 Star Wireless). Message and data rates may apply. Alert frequency may vary.

Subscribers will opt-in via the patient enrollment form from "UCB, Inc". UCB will only share this information with its representatives and agents. Message frequency will vary based on need. Text "HELP" to 844669 for help. Text "STOP" to 844669 to cancel. Messages and data rates may apply for any messages sent to you from us and to us from you. If you have any questions about your text plan or data plan, it is best to contact your wireless provider. For all questions about the services provided by this short code, you can send an email to [ONWARD@ucb.com](mailto:ONWARD@ucb.com) or call 1-844-669-2731.

Alerts sent via SMS may not be delivered to you if your phone is not in range of a transmission site, or if sufficient network capacity is not available at a particular time. Even within a coverage area, factors beyond the control of your wireless carrier may interfere with message delivery, including the customer's equipment, terrain, proximity to buildings, foliage, and weather. You acknowledge that urgent alerts may not be timely received and that your wireless carrier does not guarantee that alerts will be delivered. Carriers are not liable for delayed or undelivered messages.

UCB reserves the right to terminate this service in whole or in part, at any time, without notice.

#### **Marketing Consent (Optional):**

By checking here & providing your information, you acknowledge you are a U.S. resident and give UCB and its business partners permission to send you information or contact you and/or your healthcare provider regarding your disease as well as information on other related treatments, products and services, and for marketing and informational purposes by phone, email, or mail. You understand that UCB or its business partners will not sell your name, address, email address, or any other information to another party for their own marketing use.

## Patient Authorization to Use/Disclose Health Information (Required)

### HIPAA Authorization:\*

By signing this form, I hereby authorize each of my physicians, pharmacists (including any specialty pharmacy) that receives my prescription for a UCB medication, and other of my healthcare providers (together, "Providers") and each of my health insurers (together, "Insurers") to disclose information related to my medical condition and treatment (including prescription information), my health insurance coverage and policy number, my name, mailing and email addresses, telephone number, date of birth and Social Security Number (together, "Protected Health Information"), to UCB, Inc. and its agents, service providers, contractors and representatives (together, "UCB"), so that UCB may:

- (i) enroll me in, and contact me about, UCB medication support programs.
- (ii) provide me with educational materials, information, and services related to UCB medications.
- (iii) verify, investigate, assist with, and coordinate my coverage for a UCB medication with my Insurers and Providers.
- (iv) conduct market analyses/research or other commercial activity, including aggregating my Protected Health Information with other data for such analyses.
- (v) assist with analysis related to quality, efficacy, and safety for UCB medication.
- (vi) de-identify my Protected Health Information for use for any purpose under applicable law.

I understand that once my Protected Health Information has been disclosed to UCB, federal privacy laws may no longer protect the information and it may be subject to re-disclosure. I understand that one or more Provider and/or Insurer may receive payment from UCB for disclosing my Protected Health Information for some or all of the purposes listed above.

I understand that I am not required to sign this Patient Authorization to Use/Disclose Health Information Authorization, and that if I decline to sign, that will not affect my treatment (including the receipt of UCB medication), payment for treatment, insurance enrollment, or eligibility for insurance benefits, but it may mean that I will not receive the other services described above.

I understand that I may cancel (revoke) this Authorization at any time by calling ONWARD at 1-844-669-2731 (1-844-ONWARD1) or mailing a letter with my notice of withdrawal to ONWARD, 50 Bearfoot Road, Northborough, MA 01532.

UCB shall provide timely notification of my cancellation (revocation) to my Providers and Insurers. Once my Providers and Insurers receive and process the notice of cancellation (revocation) of this Authorization, my Providers and Insurers may no longer make disclosures of my Protected Health Information to UCB as permitted by this Authorization.

However, cancelling this Authorization will not affect any action(s) taken by my Providers or Insurers based on this Authorization before receipt of my notice of cancellation. This authorization expires 10 years from the date it was signed, or such earlier date as required by applicable law unless I cancel it beforehand. I understand that I have the right to receive a copy of this Authorization when it is signed.

---

I agree to this Patient Authorization Form.

Print Patient First and Last Name: **Jane Smith**

Date of Birth: **08/13/1981**

Print Authorized Representative First and Last Name:

Patient/Authorized Representative Signature\* *Jane Smith*

Date: **07/01/2023**

